Abstract | BACKGROUND/AIMS: METHODOLOGY: The 12 patients, who underwent LRLT for the end-stage HCV liver cirrhosis from 1999 to 2007 in our hospital, were estimated about the influence of intraportal DST for re-infection of HCV. The nine persons of all patients had received the intraportal DST after LRLT. RESULTS: These nine patients could be steroid withdrawn within 2 months. The seven persons of all patients that received intraportal DST were treated with perioperative IFN therapy. Two patients had preoperative interferon-beta therapy. The one patient could obtain SVR. The other patient dropped out for the complications. The four patients had interferon-beta therapy in the acute hepatitis phase. Two patients had it in the chronic hepatitis phase. The one patient mentioned before, had preoperative IFN-beta and dropped out. HCV of the one patients without interferon therapy disappeared spontaneously from 3 months. The HCV disappeared in the 6 patients (66.7%) of all nine patients with intraportal DST after LRLT. The five of six patients were SVR. The patient who got preoperative IFN-beta revealed the macrochimerism of donor type CD56+T cell in the graft liver one month after LRLT. The immunological analysis about the patient, who got a spontaneous disappearance of HCV two months after LRLT, demonstrated that CD56+T cells strongly developed the both FasL and TRAIL expressions. CONCLUSION: In this study, the clinical and immunological findings suggested that intraportal DST might affect for the clearance of HCV by the both host immunity and IFN- ribavirin therapy.
|
Authors | Yoshinobu Sato, Hiroshi Oya, Satoshi Yamamoto, Takashi Kobayashi, Takaoki Watanabe, Hidenaka Kokai, Satoshi Yamagiwa, Katsuyoshi Hatakeyama |
Journal | Hepato-gastroenterology
(Hepatogastroenterology)
2009 Jan-Feb
Vol. 56
Issue 89
Pg. 205-7
ISSN: 0172-6390 [Print] Greece |
PMID | 19453058
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Aged
- CD56 Antigen
(immunology)
- Female
- Flow Cytometry
- Hepatitis C
(immunology, prevention & control, transmission)
- Humans
- Killer Cells, Natural
(immunology)
- Liver Cirrhosis
(immunology, virology)
- Liver Transplantation
- Living Donors
- Male
- Middle Aged
- Transplantation Chimera
- Transplantation Immunology
- Transplantation Tolerance
- Treatment Outcome
|